BTIG starts Quoin Pharmaceuticals coverage with $14 price target

what happened

TradingView reported that BTIG initiated coverage of Quoin Pharmaceuticals with a Buy rating and a $14.00 price target. The target represents implied upside of 211.1% from the stock’s October 9 closing price of $4.50.

The analyst note highlighted promising clinical results for the company’s lead product, QRX003. The treatment produced a response in two-thirds of patients with Netherton Syndrome, a rare skin disorder for which no therapies have been approved. The FDA has said that one Phase 3 study could be enough for approval, improving the prospects for a near-term NDA filing.

BTIG estimates that the potential QRX003 market for Netherton Syndrome exceeds $3 billion. Quoin could be a first mover in a largely uncontested market, while the substantial unmet need in rare diseases supports the firm’s positive view. Reference data was provided by Benzinga. This report is not a personal recommendation or investment advice.

why it matters

For markets, the note links Quoin’s outlook to clinical evidence, a potentially less demanding regulatory path and a sizable addressable market. These are BTIG’s assessments, not a guarantee of future results.

instruments